GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Reyon Pharmaceutical Co Ltd (XKRX:102460) » Definitions » Shiller PE Ratio

Reyon Pharmaceutical Co (XKRX:102460) Shiller PE Ratio : 29.35 (As of Jun. 07, 2024)


View and export this data going back to 2010. Start your Free Trial

What is Reyon Pharmaceutical Co Shiller PE Ratio?

As of today (2024-06-07), Reyon Pharmaceutical Co's current share price is ₩13450.00. Reyon Pharmaceutical Co's E10 for the quarter that ended in Mar. 2024 was ₩458.28. Reyon Pharmaceutical Co's Shiller PE Ratio for today is 29.35.

The historical rank and industry rank for Reyon Pharmaceutical Co's Shiller PE Ratio or its related term are showing as below:

XKRX:102460' s Shiller PE Ratio Range Over the Past 10 Years
Min: 14.59   Med: 34.62   Max: 117.14
Current: 31.25

During the past years, Reyon Pharmaceutical Co's highest Shiller PE Ratio was 117.14. The lowest was 14.59. And the median was 34.62.

XKRX:102460's Shiller PE Ratio is ranked worse than
64.04% of 534 companies
in the Drug Manufacturers industry
Industry Median: 23.85 vs XKRX:102460: 31.25

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Reyon Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2024 was ₩18.000. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is ₩458.28 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Reyon Pharmaceutical Co Shiller PE Ratio Historical Data

The historical data trend for Reyon Pharmaceutical Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reyon Pharmaceutical Co Shiller PE Ratio Chart

Reyon Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 33.98 62.18 41.54 34.66

Reyon Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 34.39 31.61 31.29 34.66 33.28

Competitive Comparison of Reyon Pharmaceutical Co's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Reyon Pharmaceutical Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reyon Pharmaceutical Co's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Reyon Pharmaceutical Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Reyon Pharmaceutical Co's Shiller PE Ratio falls into.



Reyon Pharmaceutical Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Reyon Pharmaceutical Co's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=13450.00/458.28
=29.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Reyon Pharmaceutical Co's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Reyon Pharmaceutical Co's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=18/118.8477*118.8477
=18.000

Current CPI (Mar. 2024) = 118.8477.

Reyon Pharmaceutical Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 157.617 99.353 188.544
201409 189.291 99.608 225.853
201412 157.617 99.098 189.029
201503 226.998 99.720 270.539
201506 190.045 100.050 225.751
201509 222.474 100.110 264.115
201512 23.379 100.220 27.724
201603 241.327 100.560 285.214
201606 135.747 100.790 160.068
201609 133.484 101.460 156.360
201612 115.297 101.560 134.923
201703 208.899 102.850 241.392
201706 156.109 102.610 180.813
201709 282.805 103.490 324.773
201712 97.275 102.990 112.253
201803 48.039 104.100 54.845
201806 226.471 104.130 258.480
201809 27.451 105.650 30.880
201812 -235.294 104.350 -267.984
201903 157.843 104.490 179.532
201906 81.373 104.880 92.210
201909 78.431 105.200 88.606
201912 -38.235 105.120 -43.228
202003 0.980 105.540 1.104
202006 76.471 104.870 86.664
202009 49.020 106.200 54.858
202012 100.510 105.765 112.942
202103 57.000 107.357 63.101
202106 172.000 107.579 190.017
202109 1.000 108.759 1.093
202112 75.000 109.676 81.272
202203 82.000 111.806 87.165
202206 -25.000 114.083 -26.044
202209 116.000 114.831 120.057
202212 211.000 115.200 217.681
202303 109.000 116.550 111.149
202306 141.000 117.140 143.056
202309 -6.000 119.111 -5.987
202312 -54.000 118.848 -54.000
202403 18.000 118.848 18.000

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Reyon Pharmaceutical Co  (XKRX:102460) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Reyon Pharmaceutical Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Reyon Pharmaceutical Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Reyon Pharmaceutical Co (XKRX:102460) Business Description

Traded in Other Exchanges
N/A
Address
416, Yeongdong-daero, 8th floor, Gangnam-gu, Seoul, KOR
Reyon Pharmaceutical Co Ltd is a Korea-based pharmaceutical company. It is engaged in the manufacturing and distribution of specialty medicines and raw materials. The main business of the company has been divided into generic drugs, original drugs, and drug substances The key products include eye drops, injection, antibiotics, skeletal muscle relaxants, coagulation drugs, anti-inflammatory enzymes, and blood vessels dialectic drugs, among others.

Reyon Pharmaceutical Co (XKRX:102460) Headlines

No Headlines